Reveal: Frequently Asked Questions

Welcome to the Reveal FAQ video series. Do you have any questions? Get in touch!

1. What is dual-energy X-ray?

2. Why is KA Imaging’s dual-energy X-ray technology better?

3. Has Reveal been tested in a clinical environment?

4. What is DQE?

5. What does retrofittable mean?

6. Dual energy in a single exposure… how is it possible?

 

1. What is dual-energy X-ray?

Professor Karim S Karim explains dual-energy X-ray and how it improves visualization of tissue and bones.

2. Why is KA Imaging’s dual-energy X-ray technology better?

Dual-energy X-ray has been around for 30 years. However, the old dual-energy technology has some flaws that cannot be ignored: motion artifacts are relatively common, and the technology is not portable. Reveal, on the other hand, is motion artifact free and portable. Learn more in this short video.

3. Has Reveal been tested in a clinical environment?

Our president and CEO Amol Karnick presents the first clinical trial from KA Imaging.

4. What is DQE?

Our president and CEO Amol Karnick explains the importance of DQE – Detective Quantum Efficiency.

5. What does retrofittable mean?

Do you have to invest in a full new system to get dual-energy x-ray? Short answer is… NO! A retrofittable detector can upgrade your regular X-ray system.

6. Dual energy in a single exposure… how is it possible?

This looks like the one million dollar question. How did we do it? It’s an amazing engineering feat.

Read more

8 Features That Make Reveal Able To Join The Fight against COVID-19

Canadian manufacturer KA Imaging is seeking clinical and government partners for trials

With numbers still climbing, the novel Coronavirus has reached more than 2 million confirmed cases worldwide. As the number of infections gets higher, experts from different fields are trying to find ways to help stop the disease from spreading. In the article “How Reveal’s Technology Can Help Screen For COVID-19”, KA Imaging’s CTO Karim S. Karim says that “recent experiences have shown that testing for viral RNA may not suffice as the only test to confirm or rule out the infection. This is where we can help, as radiological imaging, in some cases, has indicated presence of pulmonary disease even days earlier than PCR testing1. Moreover, radiological imaging can follow the progress of COVID induced pneumonia over time enabling timely decision making about treatment efficacy or need for ventilators”.

The company is in late stage discussions to start clinical trials on the efficacy of Reveal in triaging COVID-19, and actively seeking clinical and government partners to obtain the necessary clinical evidence to determine deployment conditions and to accelerate adoption.

Reveal is undergoing IEC testing and will be submitted to the FDA for US 510K regulatory clearance in 2020.

The following list presents Reveal’s most important features, which could be helpful in the current crisis.

1. Dual-energy subtraction radiography

KA Imaging’s portable Reveal X-ray detector uses dual-energy subtraction radiography, a digital X-ray technique that is widely known for classifying lung nodules for diseases like lung cancer, pneumonia and tuberculosis.

2. One exposure, three images

With one shot, Reveal provides high-quality traditional X-ray, bone subtracted (which is ideal for pulmonary disease diagnosis), and tissue subtracted.

 

3. Motion artifact free

Motion artifacts are streaks due to breathing motion that invalidate images and mislead radiologists. The flaw is possible when using conventional dual-energy X-ray systems

4. High DQE = less radiation

Ability to acquire an image with 50X less radiation than CT.

5. Portable

The Reveal detector can be moved to a patient’s bedside or used in the field.

6. Retrofittable

Reveal can be retrofitted into existing X-ray equipment within a few hours. There are 500,000 conventional X-ray systems globally with more than 10,000 installed in Canada even in remote areas.

7. Cost-effective

Conventional dual exposure dual-energy systems can cost as much as half a million dollars and require dedicated rooms. Reveal, on the other hand, has a list price of $125,000 USD.

8. Promising initial results in clinical trial

In October 2018, KA Imaging started a clinical trial at Grand River Hospital in Kitchener, Ontario, Canada to image lung cancer patients with Reveal. The initial results are promising. Watch some of them in the short video below.


 Click here to learn more about Reveal.

References:

  1. Wong, H. Y. F., Lam, H. Y. S., Fong, A. H.-T., Leung, S. T., Chin, T. W.-Y., Lo, C. S. Y., … Ng, M.-Y. (2020, March 27). Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients. Retrieved from https://pubs.rsna.org/doi/10.1148/radiol.2020201160
Read more

Advantages Of Phase Contrast: A Few Examples

inCiTe™ is a world-first phase-contrast benchtop micro-CT. Using KA Imaging patented technology, this X-ray microscope excels at imaging materials that have poor X-ray absorption, such as biomaterials, polymer composites and other low-density samples. inCiTe is also the first commercial micro-CT to utilize BrillianSe™, the highest spatial resolution direct conversion X-ray detector in the world for hard X-rays, that allows for true unmagnified resolution down to 8μm.

Why phase-contrast?

When an object is placed in front of an X-ray source, the shadows, or projections, of the object can be captured by a detector in the background. Computed tomography, also known as CT, is the process of reconstructing an image representation of the object from its X-ray projections using computer algorithms.

The primary advantage of the phase-contrast paradigm is that when an object presents poor conventional absorption-contrast (e.g. soft biological tissue or other low-density materials such as polymers), contrast can instead be generated with higher sensitivity using phase-contrast techniques.

inCiTe™ achieves phase-contrast directly by free-space propagation of the X-ray beam, transforming X-ray phase changes due to the object into X-ray intensity variations at the detector.

The result is an image with much more detail, which wouldn’t be possible using conventional CT techniques.

Watch the video below to see some images and the results of inCiTe.


Contact us to learn more!

Read more

KA Imaging Employees Work From Home Amid COVID-19

UPDATE April 04 2020: The office is still closed. Work and meetings will continue online until further notice. 

==

Office will be closed until the end of March; period can be extended

In response to the emergence in Ontario of COVID-19, all KA Imaging employees are working from home for the next two weeks starting today. Work and scheduled meetings will continue online.

The Waterloo-based company has around 30 employees, 20 of whom work directly in the office. “The outbreak is growing. We need to be cautious and ensure we take the necessary steps to protect the health of our team and our community,” says Amol Karnick, president and CEO of KA Imaging. “We are doing our part to curb and contain the spread of COVID-19 so that we can all go back to normal daily lives faster,” he continues.

The initial two-week period of home-office will be revised and may be extended, depending on how the pandemic evolves in Canada.

Read more

How Reveal’s Technology Can Help Screen For COVID-19

As the number of infections gets higher, experts from different fields are trying to find ways to help stop the disease from spreading

Picture of Karim S. Karim, CTO at KA Imaging
Karim S. Karim, CTO at KA Imaging

The latest situation report from WHO points to more than 105,000 confirmed cases globally. As the number of infections gets higher, experts from different fields are trying to find ways to help stop the disease from spreading. In this interview, KA Imaging’s CTO, Karim S. Karim, discusses how Reveal’s technology could strengthen efforts against the spread of the novel Coronavirus. Reveal is undergoing IEC testing and will be submitted to the FDA for US 510K regulatory clearance in 2020.

 

How can Reveal’s technology help diagnose of COVID-19?

Karim: Dual-energy subtraction radiography is widely known for classifying lung nodules for diseases like lung cancer, pneumonia and tuberculosis. Initial studies have demonstrated the improvement of the area-under-the-curve for detecting pneumonia from 0.84 to 0.88 by using the technique1. Thus, the use of dual-energy X-ray in COVID-19 to detect manifestations of the disease in the lungs may contribute to improve diagnosis – especially because Reveal is the only available option that is motion artifact free.

What does “motion artifact free” mean?

Karim: Current dual-energy X-ray implementations are not mainstream because they require acquisition of two X-ray exposures at different energy levels. This double-exposure leads to blurring artifacts due to heart-beating or breathing motion, producing streaks. These artifacts often invalidate the resulting images and force retakes, which is time – and money – consuming. This problem doesn’t happen with Reveal. Our detector uses a patented three-layer sandwich design to acquire images simultaneously from only one exposure. Post-acquisition imaging processing allows the creation of high-quality traditional DR, bone subtracted, and tissue subtracted images. Price also acts like a barrier. A full new dual-energy system can cost as much as half a million dollars, and not many institutions have the resources to invest in this type of high-end technology. Reveal, on the other hand, was designed to be retrofittable. It means that, for a quarter of that price, we can upgrade an existing conventional X-ray system. The install base of all conventional X-ray systems is around 500,000 globally.

Why is early diagnosis so important?

Karim: The World Health Organization says that “early epidemiologic and clinical investigations are critical to carry out early in an outbreak of a new virus”. False negative tests can play an important role in spreading COVID-19, as the patient remains untreated and in contact with others. When the virus is novel, as COVID-19, the challenges are even greater. Recent experiences have shown that testing for viral RNA may not suffice as the only test to confirm or rule out the infection. . This is where we can help, as radiological imaging, in some cases, has indicated presence of pulmonary disease even days earlier than PCR testing2. Moreover, radiological imaging can follow the progress of COVID induced pneumonia over time enabling timely decision making about treatment efficacy or need for ventilators.

What about CT?

Karim: CT is the current clinical reference standard in the detection of pulmonary manifestations of infectious diseases. Though effective, this method suffers from low availability and still exposes patients to high doses of radiation. Even moving the patient to the CT location can represent an extra risk of spreading the virus. The method is undeniably essential but developing alternatives that can increase access and safety is urgent.

What are your next steps?

Karim: A clinical trial comparing conventional X-ray, dual energy X-ray, and computed tomography (CT) is necessary to quantitatively establish the relative performance of all three radiological methods of detecting COVID-19.  KA Imaging is actively seeking clinical and government partners to obtain the necessary clinical evidence to determine deployment conditions and to accelerate adoption.

 

References:

  1. Li F, Engelmann R, Pesce L, Armato SG 3rd, Macmahon H. Improved detection of focal pneumonia by chest radiography with bone suppression imaging. Eur Radiol. 2012 Dec;22(12):2729-35. doi: 10.1007/s00330-012-2550-y. Epub 2012 Jul 5
  2. Wong, H. Y. F., Lam, H. Y. S., Fong, A. H.-T., Leung, S. T., Chin, T. W.-Y., Lo, C. S. Y., … Ng, M.-Y. (2020, March 27). Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients. Retrieved from https://pubs.rsna.org/doi/10.1148/radiol.2020201160
Read more

KA Imaging’s X-ray Detector Allows Any X-ray System to Be Upgraded to Dual-Energy

Canadian manufacturer is getting ready to launch Reveal™, enabling bone and tissue differentiation without motion artifacts

Reveal™ Dual-Energy X-ray Detector

Canadian manufacturer KA Imaging is preparing to launch Reveal, a premium X-ray detector that upgrades any X-ray system to dual-energy. “Reveal is the ideal retrofit solution as it will fit into any ISO standard size tray,” explains Amol Karnick, president and CEO of KA Imaging. Thanks to this feature, the cost of implementation can be reduced to a fraction of the price: whereas conventional dual exposure dual-energy systems can cost as high as half a million dollars, KA Imaging’s Reveal can be obtained at a quarter of this price. “You can simply replace your old detector with Reveal, as it will work with any conventional portable or fixed X-ray source,” continues Karnick.

The competitive pricing strategy is just one of the advantages. KAI developed a unique technology that can improve dual-energy X-ray images. Reveal is the world’s first portable digital detector capable of separating different energy levels with a single exposure. It delivers three images: traditional DR, soft tissue and bone. “Our patented technology eliminates the motion artifact problem often seen in traditional dual exposure dual-energy X-Ray imaging systems,” explains Dr. Karim S Karim, CTO at KA Imaging. According to Karim, the detector simultaneously enables DR images with very high DQE (detective quantum efficiency) allowing for low radiation exposures to the patient and excellent quality soft tissue and bone images.

The Reveal detector has been used clinically on more than 20 patients with lung cancer. The clinical trial is being held at Grand River Hospital in Kitchener, Ontario and is expected to scan up to 30 patients.

Reveal is being submitted to the US FDA for clearance in 2020. Radiologists globally can learn more about Reveal at the European Congress of Radiology (ECR) between March 11th to 15th at the Austria Center Vienna. KA Imaging is exhibiting at booth #G41.

ECR is one of the largest medical meetings in Europe. Canada is a featured country at this event. “We are proud that as a partner country, we are able to present Canadian technology at this year’s ECR,” says Stéphane Charbonneau, Consul and Senior Trade Commissioner at the Embassy of Canada in Vienna.

Read more
Amol Karnick, CEO (M.Eng, BASc)
Amol is a seasoned executive in the medical device industry. His experience covers the whole spectrum; from start-ups (Ultrasonix, Sentinelle Medical, Ventripoint) to large OEMs (GE Healthcare). Entering into the profession with a Bachelors in Engineering from UW and a Masters in Electrical Engineering from McGill, Amol spent 20 years in the medical imaging space to become a leader of multidisciplinary teams (sales, engineering and operations). Amol is now poised to steer KA Imaging into a position of global leadership.
Do you want more traffic?
Dignissim enim porta aliquam nisi pellentesque. Pulvinar rhoncus magnis turpis sit odio pid pulvinar mattis integer aliquam!
  • Goblinus globalus fantumo tubus dia montes
  • Scelerisque cursus dignissim lopatico vutario
  • Montes vutario lacus quis preambul den lacus
  • Leftomato denitro oculus softam lorum quis
  • Spiratio dodenus christmas gulleria tix digit
  • Dualo fitemus lacus quis preambul pat turtulis
  • Scelerisque cursus dignissim lopatico vutario
  • Montes vutario lacus quis preambul den lacus
SUBSCRIBE TO OUR NEWSLETTER AND START INCREASING YOUR PROFITS NOW!
* we never share your e-mail with third parties.
Karim S. Karim, CTO
(PhD, PEng, MBA)
A professor of Electrical and Computer Engineering at the University of Waterloo, Dr.Karim is a distinguished academician known for pioneering and commercializing large area current mode active pixel sensor technology that is now used in bio-metric fingerprint readers for mobile phones. With 20 years of experience in designing and prototyping large area digital imagers, Dr.Karim has been instrumental in raising over $12 million in research funding. A full member of the American Association of Physicists in Medicine (AAPM), Dr.Karim is also an IEEE distinguished lecturer.
Sina Ghanbarzadeh, Co-Founder
(MSc, PhD*)
Sina is the co-founder and the lead of the design team at KA Imaging Inc. He brings over 7 years of experience in design and characterization of imaging detectors to the KA Imaging Inc. He has designed the state of the art imaging detector prototype and currently leading the design team at both device and system level. Sina holds a Masters in Science degree in Electrical Engineering from the University of Waterloo and is also working towards his PhD at University of Waterloo.
Joan Medley, Quality Regulatory Expert (ISO 13485)
Joan began her career as a Medical Radiation Technologist at Sunnybrook Health Sciences, specializing in general and trauma radiography, CT scanning, angiography, heart catheterizations and fulfilled the role of clinical instructor. She has co-authored a Quality & Regulatory college course providing outline, course content and learning objectives. With over 2 decades of experience as a Quality Assurance (QA) Manager and Director, Joan has led medical device manufacturers through ISO registration and managing Quality Management systems. Certified as an ISO 13485 Lead Auditor, Joan currently provides contract services for a certification body.
Jill Zappitelli, Human Resources Consultant (CHRL)
An experienced and accredited Human Resource Professional and Program/Project Manager, Jill’s rich expertise and national and international experience in every facet of Human Resources affords her the distinction of being one of the most sought-after HR professionals in the region. As a member of the HRPA Board of Directors, her CHRL designation combined with a Business Administration Management Diploma from Conestoga College – Jill brings a genuine level of confidence to any organization that finds itself without some HR guidance. Creating and implementing authentic and effective HR solutions to solve an array of employee challenges have been Jill’s signature for several years with companies ranging from SunLife Financial to Blackberry, to non-profits such as Trellis Mental Health. Now, as a consultant to Waterloo’s emerging businesses and tech community, Jill has been delivering relevant and meaningful solutions to scale – be it program level or simply getting the right advice.
Ako S. Williams, Vice President
Ako Williams is Vice President, General Counsel and Corporate Secretary of Ushio America, Inc., which is a U.S. subsidiary of Ushio Inc. in Tokyo, Japan. Ushio is a leading provider of light sources and solutions for a wide variety of applications, including medical imaging and illumination, scientific, semiconductor, entertainment, horticulture, and architectural applications. A seasoned global enterprise executive with a strategic problem solving approach, Ako oversees Ushio America’s legal, regulatory compliance, risk management, and corporate governance matters. Previously, she was an Assistant General Counsel and Compliance Officer of Christie Digital Systems USA, Inc. (an Ushio group company) and an Assistant General Counsel of a leading home healthcare provider in the U.S. She holds a B.S. (highest distinction) from Northwestern University and a J.D. from Loyola University Chicago School of Law.
(B.S, J.D)
Ian Cunningham (BSc, MSc, PhD)
Dr. Ian Cunningham is a professor and scientist at the Robarts Research Institute at The University of Western Ontario and physicist at London Health Sciences Centre. He directs a research team of graduate students and post-doctoral fellows that are investigating new ways of acquiring and displaying medical images using digital radiography and computed tomography for improved health care.
Susan Horton (BA, MA, PhD)
Working for the World Bank got Susan interested in health and economics. Dr. Horton then proceeded to work at the International Centre for Diarrheal Disease Research in Bangladesh while writing her thesis. She has worked or taught in about 25 low and middle income countries, on topics ranging from labour markets, women's participation, benefits and costs of micronutrient interventions, and currently costs and benefits of breastfeeding, cost and cost-effectiveness of cancer interventions, and disease control priorities in low and middle income countries. Currently, Dr.Horton is working on the Disease Control Priorities project and in the past, worked on research projects with the World Bank, FAO, WHO, UNICEF, Copenhagen Consensus, etc.
Ruben Romero (CPA, CMA)
Ruben has a strong background in finance, accounting and strategic business operations from several years of work experience in various industries. Prior to joining KA Imaging's team, Ruben gained valuable experience working for Canadian and Global firms such as Class 1 Inc. and Bimbo Bakeries. Ruben has been a Chartered Professional Accountant and Certified Management Accountant for over ten years.
David Bell (PhD)
David Bell is a clinical and public health physician with a PhD in population health and background in internal medicine, modelling and epidemiology of infectious disease. Previously, he was Director of the Global Health Technologies at Intellectual Ventures Global Good Fund in the USA, Programme Head for Malaria and Acute Febrile Disease at FIND in Geneva, and coordinating malaria diagnostics introduction and scale-up with the World Health Organization in Manila and Geneva. David specializes in point of care technology development and introduction in low-resource health systems.
Evan Lee (BA, MD, MBA)
Evan Lee is a Geneva-based global health consultant. He has a BA from Harvard, an MD from New York University, and an MBA from MIT. He has worked with Médecins Sans Frontières in Kenya and Uganda and for Foundation for Innovative New Diagnostics and Management Sciences for Health. Most recently, he led Eli Lilly’s global health programs working on MDR-TB and NCDs, and founded Lilly’s 30x30 initiative to reach 30 million people by 2030.
David Koff (MD FRCPC)
David Koff (MD FRCPC) is a Professor of Radiology at McMaster University, former Chair and Chief of the department. He is founder and director of MIIRCAM, the Medical Imaging Informatics Research Centre at McMaster, and Chair and co-founder of Canada Safe Imaging. He has been a co-founder of IHE Canada (Integrating the Healthcare Enterprise) and is a member of the IHE section of the Medical Informatics Committee and RSNA. He is also a past co-Chair of the IHE International Radiology Planning Committee. Dr. Koff is fellowship trained in chest and body imaging.
Sandy Pironaggi-Trocchi (BSc)
Experienced regulatory affairs and quality assurance professional with a demonstrated history of developing and executing strategic regulatory submissions across global markets as well as implementing and maintaining quality management systems focusing on Health Canada, US FDA, MDR, MDSAP and ISO compliance.
Robert Moccia (BS, MS)
Bob brings 20+ years of management experience in the medical device industry to KA Imaging. Prior to joining KAI, Bob held various executive commercial roles with GE Healthcare in the areas of ultrasound and mammography, where most recently was the GM of Enterprise Sales. Prior to that Bob held various general management positions in Cardiovascular Ultrasound. Bob’s commercial experience at GE ranges from building and integrating startup business to rebuilding existing commercial teams. While at GE, Bob developed indirect and direct distribution models to serve customers across all market segments. Bob received his BS and MS degrees in Management from Lesley University.